April 24, 2009
 
The HIV/AIDS eNews is published by the British Columbia Persons With AIDS Society. This publication is a compilation of various articles collected from numerous news sources. Opinions and information expressed are those of the individual authors and not necessarily those of the Society.
WHAT'S  NEW  AT  THE  BCPWA

Senior's Care

seniors

Send a Message to Premier Cambell today and help the BCHC reach its goal of sending 5000 letters to the Premier!

BC's seniors and people with disabilities deserve high-quality and accessible public health care.

Take action now and send a letter to the provincial government demanding that it make critical changes to improve the lives of BC seniors and people with disabilities.


BC's Big Opt Out


BC’s Big Opt Out urges British Columbians to protect their right to privacy by refusing their personal health information be subject to eHealth, the BC Government’s new system of integrated electronic health records.

Visit their website www.bcoptout.ca to learn more about eHealth and what you can do about it.


VOLUNTEER RECEPTION

BCPWA invites our volunteers to the South Pacific: A Night in the Tropics! This year's volunteer appreciation party is all about grass skirts, songs and sarongs.

When: 6-9.30pm, Thursday April 30
Where: Holiday Inn & Suites (1110 Howe at Helmcken)
Tickets: $10 deposit for volunteers, $25 flat-rate for friends of volunteers.

For more information, contact Marc at 604.893.2298 or marcs@bcpwa.org

aidsday
calendar

WEDNESDAY NIGHT SUPPORT GROUP

The Wednesday evening group welcomes people living with HIV disease, people who are co-infected with Hepatitis C, as well as family, friends, medical or social supports of group members. The group focuses on mutual support, empowerment, and information exchange.

Date: Every Wednesday Evening
Time: 7:00pm - 9:00pm
Location: The Lounge - 2nd Floor
Address:1107 Seymour Street, Vancouver

aidsday
For more info, click here, or call 604.893.2259.

HEALING RETREAT

Healing retreats for HIV-positive men and women. Join HIV-positive people from all walks of life.

Date: June 26 - 29, 2009 and September 4 - 7, 2009
Location: Loon Lake [ Map ]
Registration: Register at reception

To book an interview:
Phone: 604.893.2200
Toll Free: 1.800.994.2437 ext. 200
Bring this completed form.

aidsday

For more info, click here.


Do You Need Better Access to Information on HIV/AIDS Treatment?

Then participate in a survey!

You can help BCPWA by participating in a research project to assess the changing treatment information needs of HIV-positive people in BC. The research examines the experiences that HIV-positive people have with access to HIV/AIDS treatment information and the quality of these experiences.

To access the questionnaire, go to:
http://infopoll.net/live/surveys/s33258.htm


FitOne - An Introduction to Active Living

Designed for individuals seeking a more active lifestyle, FitOne aims to educate participants about the beneficial effects of exercise on HIV disease while creating a mutually supportive and motivating environment.

Intended for all fitness levels, a certified kinesiologist will assess and design programs suited for individual needs. Yoga mats and exercise equipement provided. Comfortable cloths and exercise shoes recommended. Beginners welcome.

Activities may include group walks, running clinics, and beginner's yoga.

fit1

Weekly sessions begin Wednesday, February 25, 2009 from 3 – 4pm in the BCPWA Training Room

For more information, please contact elginl@bcpwa.org or call 604.893-2225. Limited number of participants. Register now.


SUITS

Join us at our next monthly networking event for professional, gay HIV+ men!

Where: Fraser Downs Racetrack

When: Saturday, May 2, 6:30-11:00PM

RSVP: (required) 604.893.2258

For more information call 604.893.2200

aidsday
calendar

SPIRITUAL WORKSHOP

Non-denominational, supportive, unique and fun.

Join other HIV+ men and women, lakeside at the Bethlehem Retreat Centre on Vancouver Island for a 3-night/ 4 day workshop devoted to personal spirituality. A provocative, progressive workshop created on the teachings of Mathew Fox. People come away renewed with a sense of hope, a feeling of global community and a boost to their self-esteem.

spiritposter

Workshop designed and facilitated by United Church Ministers, Rev. Tim Stevenson, and spouse Rev. Gary Paterson, Minister St. Andrew's Wesley United Church. Taking time to laugh and to listen, their knowledge and kindness enhances learning and garners trust.

Organized by BCPWA Retreat Team.
Lodging and meal hosted by the Benedictine Sisters.
Transportation provided.

Spaces go quickly.

Interviews March 2-April 10, 2009.
Register for an interview 604.893.2200 or 1.800.994.2437.


LEND YOUR VOICE

Survey on Employment Issues for People Living with HIV/AIDS

People living with HIV are invited to participate in an online survey on HIV and employment in Canada. The purpose of this survey is to learn more about the education, training, employment and health needs of people living with HIV. Our ultimate goal is a national network that will provide employment support, information and advocacy opportunities for people living with HIV whether in or out of the workforce. Your responses to the survey will inform us on the employment-related issues that matter to you most.

The survey is available electronically and will take approximately 25 minutes to complete. You will be able to save survey responses and then submit the final version at a later date. If you would like to request a hardcopy of the survey please send your contact information to the address below.

You do not have to give personal information and we do not plan to publish personal information. If this plan changes, we will only do so with your agreement. You have the right to opt out of any question(s) at any point throughout the survey. You may choose to provide us with contact information if you would like to be kept updated on the progress of this project.

The link to the survey is provided below. The survey will be open for responses through Friday, March 13. This opportunity is unique to people with HIV. We look forward to your response to the survey.

http://www.surveymonkey.com/s.aspx?sm=BxPMtNFSCtrk5n1CZTiWPQ_3d_3d

  more... []

LOCAL  &  NATIONAL  eNEWS

Cut ties between Health Canada, drug companies, grieving MP urges
Young is seeking an independent drug agency that gets no money from the pharmaceutical industry and is focused on keeping Canadians safe when using prescription drugs. It would be similar to the Transportation Safety Board.

April 20, 2009

  girl
Vanessa Young was taking a medication called Prepulsid when she died suddenly at age 15.

A federal Conservative MP whose 15-year-old daughter collapsed and died after taking a prescription medication will this week introduce a private member's motion calling for an arm's length drug safety agency.

Vanessa Young died in a hospital in Hamilton, Ont., in March 2000. Her father, Oakville MP Terence Young, believes a medication called Prepulsid or cisapride prescribed by their family doctor contributed to her death.

"She jumped up to go upstairs and fell down in front of me," Young recalled on CBC Radio's Metro Morning on Monday. "Her heart stopped dead."

At the hospital, doctors repeatedly asked the family who prescribed the drug. It was given to Vanessa to treat her mild form of bulimia, which sometimes caused her to feel bloated after eating.

As one of the doctors left the hospital the next day after Vanessa died, Young asked the doctor about the drug. The doctor's response — "Well, they dish it out like water" — led Young to start investigating adverse drug reactions.

Adverse reactions cause 10,000 deaths a year in Canadian hospitals when drugs are used as prescribed, Young said. Probably another 10,000 deaths occur outside of hospitals from prescribing errors and adverse reactions, he added, noting less than one per cent of reactions get reported.
'Pray that I'm persuasive'

"It's kind of a dream for me to be in the Parliament of Canada because those of us who worked on prescription drug safety for such a long time, we were in the wilderness," said Young, who is also the author of a new book called Death By Prescription.

"I can go directly to the decision-makers and I pray that I'm persuasive."

Young is seeking an independent drug agency that gets no money from the pharmaceutical industry and is focused on keeping Canadians safe when using prescription drugs. It would be similar to the Transportation Safety Board.

Young outlined several issues he has with drug safety in Canada, including:

  • Official prescribing information documents for doctors that run to 50 pages of fine print, leading many physicians to rely on drug sales representatives for their information.
  • Changes in Health Canada's mandate dating to 1997 that ordered the department to partner with pharmaceutical companies to help them market their drugs.
  • A lack of independent checks into the safety of prescribed drugs.
  • Pressure on Health Canada's drug reviewers to get drugs to market faster, since pharmaceutical companies pay for 60 per cent of drug reviewers.
  • Pharmaceutical company safety information is considered a commercial secret by Health Canada, as opposed to the U.S. Food and Drug Administration that makes the information available on the internet.
Health Canada reviewers "view themselves as helping the companies sell drugs, which in many cases is the antithesis of public health," Young said.

Also Monday, pharmaceutical industry critic Dr. Joel Lexchin said Health Canada's approach to drug regulation puts too much emphasis on speeding up drug approvals and not enough on checking the safety of drugs already on the market.

Lexchin, who teaches at Toronto's York University, said Health Canada can't make a drug company recall medications from store shelves or compel a company to change safety labels on approved drugs.

Health Canada said Lexchin's critique doesn't take into account the department's recent efforts to track drug safety after a product has been approved.

The regulator has the authority to withdraw a drug's licence, which means companies generally comply with requests to change drug labelling, said Dr. Marc Berthiaume, director of Health Canada's marketed pharmaceuticals and medical devices bureau.

Last year, Health Canada told CBC News that its mandate is to bring additional safety information to the prescriber, but the way doctors handle that information is part of their professional autonomy.

Prepulsid was pulled from the market in Canada in August 2000.

http://www.cbc.ca/
  more... []

B.C.'s AIDS heroes honoured at AccolAIDS 2009

April 20, 2009

Last night, the hardworking heroes of B.C.'s AIDS movement were recognized and celebrated with awards at the eighth annual AccolAIDS gala, held at the Fairmont Hotel Vancouver.

Vancouver's First Lady of Glam, Symone, entertained the audience in style with musical numbers from Diana Ross and also hosted the evening

While attendees enjoyed a four-course dinner, flowing bottles of wine, and a jovial atmosphere, there were also poignant moments, a few tears, and heartfelt messages about the current state of HIV and AIDS in British Columbia.

The PHS Community Services Society won the first award of the evening, in the category of Social/Political/Community Action. David Eby of the Pivot Legal Society, armed with a tambourine, presented the award by turning his presentation speech into a rap (resulting in much laughter). PHS has helped people living in Vancouver's Downtown Eastside since 1993.

The philanthropy award went to Kim Osborne, founder of Chefs for Life, which has raised more than $700,000 in funds for the Vancouver Friends for Life Society, a non-profit wellness centre for individuals with life-threatening diseases.

In the media category, there was only one nominee: Xtra! West. Editor Robin Perelle accepted the award with columnist Tony Correia, who chronicles his life with HIV in the newspaper. Perelle pointed out that much of the mainstream media's attention focuses on the criminalization of HIV, but fails to investigate why some people with HIV continue to feel the need to conceal their status. Correia added that while HIV status is often asked, the feelings of those living with HIV are often not inquired about.

Boys 'R' Us won the Health Promotion and Harm Reduction award. The organization was created to fill in the lack of services available for male and transgendered sex workers.

Dr. Mark Tyndall, one of the foremost experts on HIV, won the Science/Research/Technology award. Tyndall has researched HIV care for intravenous injection drug users and marginalized populations, and worked in Africa as well as the Downtown Eastside.

Vancouver's Maximally Assisted Therapy Program won the Innovative Programs & Service Delivery Award. The MAT Progam helps Downtown Eastside HIV–positive individuals with access and adherence to antiretroviral therapy.

The Kevin Brown PWA Hero Award went to the chair of the board of directors for the Positive Women's Network, Kath Webster. Webster has worked as part of BCPWA's Treatment Information Program, conducted Body Mapping workshops, volunteered for the AIDS Walk For Life for a decade, and is involved with the Pacific AIDS Network.

The Unsung Heroes Award was posthumously awarded to Andrew (AJ) Johnson. Among Johnson's extensive list of work in the field of AIDS and HIV, he worked as executive director of AIDS Vancouver; worked at the Dr. Peter Centre, Vancouver Community College, and St. Paul's Hospital; and was a founding member of the Canadian Association of Nurses in AIDS Care.

Over the course of the evening, funds from a silent auction and a live auction (conducted by CBC's hilarious Fred Lee) totaled a record amount of $102,840.

The evening was presented by the BC Persons With AIDS Society and GlaxoSmithKline in partnership with Shire Canada.

By Craig Takeuchi, http://www.straight.com/
  more... []

Government of Canada Announces Renewed Support for Canadians Volunteering Overseas
The Honourable Beverley J. Oda, Minister of International Cooperation, today met with senior representatives of Canadian Volunteer Cooperation Agencies (VCAs) and marked National Volunteer Week by announcing the renewal of the Volunteer Cooperation Program over 5 years.

April 22, 2009

Ottawa - The Honourable Beverley J. Oda, Minister of International Cooperation, today met with senior representatives of Canadian Volunteer Cooperation Agencies (VCAs) and marked National Volunteer Week by announcing the renewal of the Volunteer Cooperation Program over 5 years.

"Canadians have always volunteered to improve the lives of those living in poverty around the world. This reflects the best of our Canadian values." Minister Oda said. "I am pleased that the renewal of the Volunteer Cooperation Program, with the help of Canadian NGO partners, means Canadians will continue to contribute their diverse experience to help those in developing countries."

The Volunteer Cooperation Program will help leverage the skills and expertise of volunteers across sectors, including fighting HIV/AIDS, malaria and other diseases; promoting economic growth and self-reliance, education and training programs. The additional support will allow the volunteer cooperation agencies to increase the number of volunteers from approximately 2,500 to 8,500.

"Canadian volunteers are Canada's ambassadors, often living in remote villages and rural communities, working side by side with the people they have gone to assist," added Minister Oda.

The government of Canada is committed to delivering aid that is effective, focused and accountable. CIDA will work with the Volunteer Cooperation Agencies to ensure the number of volunteers is maximized over the course of the next 5 years, to meet the volunteer placement targets.

Backgrounder:
Canada Committed to Supporting Overseas Volunteer Cooperation

The Government of Canada has renewed the Volunteer Cooperation Program that provides ongoing financial support to the Canadian volunteer cooperation agencies.

The Canadian International Development Agency (CIDA) will provide $244.6 million over five years, a significant increase over the $42 million that was provided between 2004 and 2009. The funds will support eight programs managed by nine volunteer cooperation agencies. Approximately half of the current programming is carried out in Africa and one-third in the Americas.

The program will leverage the skills and expertise of an estimated 8,500 volunteers. The volunteer cooperation agencies aim to define and meet local needs through placements of qualified volunteers and volunteer-exchange programs. By engaging a large and diverse spectrum of Canadian volunteers, these agencies promote a better understanding of international development issues to the Canadian public. Through their strong connection to communities in developing countries, the agencies are also well placed to identify emerging priorities and offer innovative programming.

A mid-term evaluation of the Volunteer Cooperation Program was completed in 2007, confirming that Volunteer Cooperation Program is making a significant positive contribution to development in partner countries. Over the course of the current program, there has been strong collaboration amongst volunteer agencies. In West Africa, they worked together on a shea butter marketing and production project. A similar initiative focused on HIV/AIDS and involved partners from across Africa and Canada. In Canada, agencies have developed a joint website and organized training and educational events together.

CIDA, http://www.marketwire.com
  more... []

Top court ends government pot monopoly
Canadians who are legally permitted to smoke pot to treat illness won a victory in the Supreme Court of Canada on Thursday when it refused to hear an appeal of a ruling that put an end to the federal government monopoly.

April 23, 2009

The federal government has been under pressure to clarify the rules around medical marijuana use in public. One recent request for clarification came from a bar owner in Burlington, Ont., who faced allegations of discrimination when he asked a medical marijuana user not to smoke outside his business.
The federal government has been under pressure to clarify the rules around medical marijuana use in public. One recent request for clarification came from a bar owner in Burlington, Ont.,
who faced allegations of discrimination when he asked a medical marijuana user not
to smoke outside his business.
Photograph by: Mark Blinch, Reuters

OTTAWA — Canadians who are legally permitted to smoke pot to treat illness won a victory in the Supreme Court of Canada on Thursday when it refused to hear an appeal of a ruling that put an end to the federal government monopoly.

A three-judge panel, without giving reasons, rejected the Justice Department's application to challenge a Federal Court of Appeal decision that gave licensed producers the right to grow marijuana for more than one patient.

The Supreme Court's decision to stay out of the matter effectively upholds the 2008 ruling, which dismissed the government's argument that the industry would be thrust into deregulation if the court loosened federal restrictions.

The decision was a victory for a group of patients who challenged the federal regulations, arguing that the government-issued pot, supplied by Prairie Plant Systems in Manitoba, is too weak and that they should have the option to find their own supply.

The appeal court decision struck down government regulations that authorized users who cannot grow their own marijuana to designate a grower, or obtain government-issued weed.

The patients sought the right to buy marijuana from Carasel Harvest Supply Corp., which, under the current regime, was not allowed to supply more than one patient with medical marijuana.

There are about 2,000 people legally allowed to use marijuana for medical purposes, but the lower court found only 20 per cent buy it from the government supplier.

Justice Department lawyer Sean Gaudet argued in the appeal court that statistics weren't enough to conclude the government-supplied marijuana was inadequate, or forced people to seek drugs on the black market.

Moreover, sanctioning growers to supply more than one patient would allow the industry to develop "without safeguards" and exacerbate the risk that marijuana will be diverted to improper use, he said.

By Janice Tibbetts with files from Jordana Huber, http://www.theprovince.com
  more... []

INTERNATIONAL NEWS

U.N.: Prisons Are Creating an HIV Time Bomb
Around 30 million people globally are incarcerated at any given time, and HIV is a severe problem in prisons, according to UNODC. If prisons are a reflection of society as a whole, “we are seeing a disaster around the world,” said Costa.

April 17, 2009

U.N.: Prisons Are Creating an HIV Time Bomb | HIVPlusMag.com News

On Thursday, the head of the United Nations Office on Drugs and Crime (UNODC) warned the spread of HIV through drug use in prisons around the world is a “health bomb.” When infected inmates are released, they pose a risk to the communities they return to, Antonio Maria Costa told Reuters.

Around 30 million people globally are incarcerated at any given time, and HIV is a severe problem in prisons, according to UNODC. If prisons are a reflection of society as a whole, “we are seeing a disaster around the world,” said Costa.

Prison overcrowding is a serious problem, especially in Africa and Central America. Some prisons in these regions house up to 10 times the number of inmates they were built for, said UNODC. One facility Costa visited in Port-au-Prince, Haiti, was built for 420 prisoners but contained around 4,000. Inmates there had to stand because the cells were so crowded and had nowhere to sleep, he noted.

Costa said countries should follow U.N. guidelines on how prisons should be run and how inmates should be treated. In addition, the problem of overcrowding can be eased by alternative punishments for minor crimes, he said.

http://www.hivplusmag.com

  more... []

Fight against syphilis, AIDS goes online
As life moves to the Internet, a growing number of public health agencies are signing on to social networking sites — not to find friends but to fight syphilis, AIDS and other sexually transmitted diseases.

April 18, 2009

Cincinnati - As life moves to the Internet, a growing number of public health agencies are signing on to social networking sites — not to find friends but to fight syphilis, AIDS and other sexually transmitted diseases.

Public agencies in Ohio are among the latest to open accounts on online meeting sites in an effort to reach people who may have a sexually transmitted disease and need medical care.

Cleveland's health department opened accounts on two sites this week, and Cincinnati has plans to start an online effort in a couple of months. Columbus Public Health established a presence a year ago on Manhunt, a social networking site for gay men, and has since added other popular sites.

Debra Mullen, who handles online notifications for Columbus Public Health, contacted a man a year ago who did not know he had syphilis. She heard from him again this week.

"He got treatment and now is asking whether he needs any follow-up," she said.

Traditionally, health departments have used letters and telephone calls to set up preferred face-to-face meetings with the partners of infected people who visit their clinics, test positive for a sexually transmitted disease, and reveal their partners' names to health officials.

But with the Net, the encounters may occur between people who know only each other's online names. Even with that small piece of information, health officials can go to the site, send a message to someone's partner, and advise him or her to contact health officials and provide contact information.

Daniel Pohl of Howard Brown Health Center in Chicago recalls two instances where online notification has done more good than expected.

"One client I was in contact with over a couple of months was an escort. I was able to get him to come in for syphilis testing, and he was infected," said Pohl, the center's manager of disease intervention services. "He was treated for that, but was too afraid to get tested then for HIV."

Over time, the man agreed and tested positive for HIV a year or so ago when he was 19, Pohl said. "He not only became very involved with his own care, but also got involved with a program that helps other young people with HIV."

Pohl said another man who lived with an emotionally abusive male partner was notified and tested negative for HIV and syphilis, but agreed to see a counselor in the center's domestic violence program.

"Sometimes the person on the other end of the e-mail may be completely isolated from support services, and this may help them in many ways," Pohl said.

The National Coalition of STD Directors, consulting with the Centers for Disease Control and Prevention, developed guidelines in 2007 to help public health departments create profiles for confidential online notification. Health officials say the notification cost is minimal — a few thousand dollars for a computer and DSL line dedicated to the program.

Rachel Kachur, a researcher with the CDC's STD prevention division, said she is encouraged more health departments are moving to online notification, but the work is not happening fast enough.

"The national guidelines help by giving local areas a jumping off point where they can tweak them to fit their needs," she said. "But the goal is to get everyone doing this."

Health departments in San Francisco, Washington, D.C., and Massachusetts were among the first to begin using social networks to reach a possibly infected person. The Web sites typically used cater to gays and bisexuals, such as Manhunt and Adam4Adam, but some officials hope to eventually reach the heterosexual population as well.

Cleveland, which has seen a rise in syphilis, started a presence on Manhunt and Adam4Adam this week, said David Merriman, project coordinator overseeing HIV/AIDS services for the city.

"Our goal is to also be on sites like Facebook where we could reach broader populations, including heterosexual adults and adolescents who wouldn't use sites like Manhunt," Merriman said.

In Massachusetts, the state health department has reported a good response since initiating partner notification on Manhunt in 2006. Kevin Cranston, director of the department's infectious diseases bureau, says well over 50 percent of those the agency contacted online responded, with some getting department-documented medical evaluation and treatment and others saying they would seek medical evaluation on their own.

By Lisa Cornwell, The Associated Press, http://www.google.com
  more... []

Young, Positive and Homeless
Efforts to provide care for HIV-positive youth work best with a full range of services, so the program is not stigmatized as HIV-specific. Homeless LGBT youth are at such high risk of HIV infection because of the catastrophic merging of risk factors that homelessness adds to their lives. Addressing their homelessness is an important first step toward HIV testing and care. The terrible lack of safe and appropriate emergency housing for homeless LGBT youth is a public health crisis that we must address if we ever hope to stem the spread of HIV.

Winter 2008/2009

homeless

To understand the impact of homelessness on youth and HIV, we turned to two New York City experts with hands-on experience. Kate Barnhart is the former Director of Sylvia's Place, an emergency shelter for lesbian, gay, bisexual, and transgender (LGBT) youth, and Carl Siciliano is the Executive Director of the Ali Forney Center, which provides housing and supportive services to homeless LGBT youth.

How widespread is the problem?

Carl: Nationally, a 2002 estimate found close to 1.7 million homeless and runaway youth, most between the ages of 15 and 17. Just about 6% of them identified as LGBT. The New York City Council recently counted over 3,000 homeless youth in the city, and a third of them are LGBT. Homeless youth in general are at greater risk for HIV than their peers, and homeless LGBT youth are at particular risk. The National Coalition for the Homeless estimates that the rate of HIV infection is 3% to 20% higher among the homeless.

Kate: Homeless youth have a higher risk of getting HIV because many turn to "survival sex" at some point. Whether they're having sex for money, drugs, or a place to stay, they're often not in a position to demand a condom. A large number have lived with older sexual partners. Although they may consider these relationships romantic, being dependent on another person for housing makes them vulnerable, especially when it comes to safer sex. We have had several cases of young people who lived with older "boyfriends" who demanded unsafe sex, only to discover the partners' HIV status later, by finding things like medication or ADAP cards.

Carl: Many survive through sex work. Even those who don't do sex work tend to have many sexual partners. Studies show that LGBT homeless youth have higher rates of substance use. They also suffer from higher rates of mental illness, and experience more violence and trauma. These factors create a perfect storm of risk factors. In fact, about 25% of the clients receiving emergency housing and drop-in services at our center are known to have HIV.

Does just being homeless increase their risk of getting HIV?

Carl: Being homeless increases the instability of their lives, and there are fewer than 100 beds available to this population in New York City. So LGBT youth find themselves in a fearful, chaotic situation that makes it very difficult to cope with a positive test result. It seems very clear that the lack of safe emergency housing is the greatest cause of their high rate of HIV. Unstable housing is also the greatest barrier to their learning their HIV status and responding in a healthy manner.

Kate: Homeless young people are also likely to use drugs and alcohol. This increases the risk of getting HIV, whether directly, through shared needles, or indirectly, by removing inhibitions and impairing decision-making skills.

Homeless transgender youth face other risk factors. Since they lack the stability and resources needed to make their gender transition under a doctor's care, they may turn to street sources for hormones and silicone, and may inject them with unclean syringes.

All of these risks can be lowered by using harm reduction methods, but this requires education. Since many homeless adolescents drop out of school, whether because of the homelessness itself, anti-gay/anti-trans harassment, or for other reasons, school-based HIV education may not reach them. Most youth shelters and drop-in centers offer HIV testing and education, but this only reaches those who use these services.

Do we need more HIV testing efforts?

Carl: It would stand to reason that these young people should be tested. But they often view testing with fear and anxiety. I recall a young homeless trans woman who asked for an HIV test. When we did pre-test counseling, she said that if she got a positive test she would kill her boyfriend, who she thought infected her. We didn't test her, but instead offered her mental health counseling. Well, she went to another test site, found out she was HIV positive, and came back to our center and stabbed her boyfriend. Luckily, he was not seriously injured.

Kate: Far from lacking access to HIV testing, homeless youth are, in my opinion, over-tested. According to our intake database, 95% of our clients report that they've been tested recently. Many get tested several times each month, which does not make much sense medically but does makes sense for someone who needs an incentive like a subway fare card.

Incentives bring other problems, too. A young person focused on getting one may not be thinking of the possibility of testing positive. One young man at our shelter took an HIV test to get $5 for lunch money, tested positive, and tried to hang himself in our bathroom that night. This is an example not only of the potential problems of incentives, but also of the lack of follow-up services for those who do test positive.

Carl: Even after pre-test counseling, three of the last ten people to test positive here were hospitalized because of a desire to commit suicide. This is clear evidence of the need to link HIV testing with mental health counseling.

Testing is dangerous without establishing trust, and that means addressing more pressing issues like homelessness first. Providing a sex-positive environment that is accepting and confidential builds a sense of community and trust. For example, one of our clients, A.J., was kicked out of his mother's house because of his sexual orientation. He turned to sex work to support himself and began binge drinking to cope with depression. After bed-hopping for some time, he heard of the Ali Forney Center and came in for an intake.

A.J. was tested for HIV within a month of his arrival and found out he was positive. We were able to provide housing and primary care, along with mental health counseling. But while he had stable housing and access to regular health care, A.J. would fall out of mental health therapy frequently. He was battling depression and still occasionally did sex work. He was not disclosing to family, friends, or sex partners.

After many discussions with us, he restarted mental health therapy, and this time stuck with it. He developed new coping skills for his depression. After time, he also began to accept his HIV diagnosis and was able to start to disclose to important people in his life. Two years after learning his diagnosis, A.J. now has permanent housing, adequate health care, and a job. He still goes to therapy, and discloses to his sex partners.

So testing doesn't help unless young people get the services they need. Are those services available?

Kate: While there are several excellent programs for young people with HIV, connecting our clients with these programs takes work, like convincing them to attend, getting their documents (many homeless youth lack birth certificates, Social Security cards, etc), completing referral paperwork, and escorting them to the first appointment, at least. And while they wait to be accepted, the shelter or drop-in program must do the work of supporting them through the initial crisis, even though these programs often do not receive funding for these services.

There is an urgent need for services that can be obtained quickly, with little or no documentation, on a walk-in basis. Walk-in services are especially needed for mentally ill and substance-using youth, and those involved in sex work. These individuals often have great difficulty keeping appointments due to the chaotic nature of their daily lives and the lack of basic items like watches, appointment books, calendars, or alarm clocks. If you're sleeping on the subway, it can be difficult to know what day it is, never mind what time it is. And homeless young people who are aware that they have an appointment frequently do not have the subway fare to get there. Services for homeless youth are most successful when provided where they gather, or within walking distance.

Is it possible for a homeless young person to get good medical care?

Kate: They do have difficulty obtaining medical care in a consistent manner. They often rely on emergency rooms or see medical providers only haphazardly -- a medical van one week, the doctor at a shelter the next -- depending on what program they are currently attending.

Adherence to medication is also a huge issue for homeless youth. It's hard for a young person in a shelter to take medication confidentially, since residents may be required to give medication to staff for safekeeping or may be seen by peers. Some meds require refrigeration, with often only a shared refrigerator available. Young people living on the street or moving from place to place may have their possessions stolen, including medications that are very difficult to replace.

Carl: Access to emergency housing is critical in getting clients to a place where they can accept a positive test result and stay in care. Housing provides a way to reduce continued harm from sex work and drug use by giving them much more stability in their lives. It's clearly linked with better health outcomes for people with chronic illnesses. It is the bedrock on which access to care, HIV treatment, and entry into the job market are built.

Kate: We recently had a young man disappear from a shelter, leaving behind his medications. By the time he returned (he had been staying with a man he met in a bar), he had missed so many doses that it was necessary to change him to a new regimen. Medication side effects can be especially difficult for homeless kids since they lack easy access to bathrooms and must rely on public restrooms or share a shelter bathroom with many others. Also, most youth shelters require clients to be out of bed by a certain time and are closed during the day, so there is no opportunity for rest if needed.

How do they deal with disclosure?

Carl: Many LGBT youth experience rejection when they come out about their sexuality. They sometimes end up homeless as a result. And those with HIV find it hard to disclose their status, often for the same reasons that kept them from getting tested. It comes as no surprise that many are afraid of yet another layer of rejection. HIV is still heavily stigmatized, and disclosure comes with great risks. For example, family and friends often find it hard to cope with such news, and turn to others for comfort. Too often, news spreads quickly and youth find themselves betrayed and full of shame.

Family and friends often incorrectly expect that simply being LGBT will lead to HIV infection, and HIV is still misunderstood as a death sentence. Young people with HIV often feel like they let themselves and their loved ones down at a time when their spirits need lifting. And these young people not only have to deal with rejection and homelessness, but many are born in low-income neighborhoods with high crime rates. They may already have a fatalistic sense of what the future brings. Testing HIV positive turns an already bleak vision of one's future into "doom."

How does having HIV affect their self-esteem?

Kate: A large majority of our clients experienced childhood sexual abuse or rape. This is a documented risk factor for later HIV infection, since it can reduce personal boundaries and sense of self-worth. Self-worth among homeless youth is also negatively affected by other traumatic experiences, including emotional and physical abuse in childhood, death of caretakers, homophobic and transphobic harassment, violence on the street, and police brutality. Homeless young people are frequently arrested for offenses ranging from sleeping in public places to more serious crimes, and they are at risk for being raped in jail -- particularly transgender women, who are housed in male units.

Carl: As we mature, we tend to gain ego strength and a sense of self that comes from who we know ourselves to be. Teens are less likely than adults to have gained this ego strength. They are more likely to allow their sense of worth to be based on how others view them. As a result, they can be deeply afraid of the stigma of HIV. Homeless LGBT teens already face terrible rejection from their families and communities. They often find much of their self-esteem in their sexual desirability. Being desired sexually is one of the very few areas where they feel wanted and in control.

As a result, many of these young people will refuse to return to a program where the staff or other clients know they have HIV. Often, when a young person is given a positive test result, that's the last time she or he is seen at that program. In addition to providing a barrier to testing, this refusal to be seen by others as HIV positive also creates a barrier to housing designed for people with HIV. They think living there "outs" them in the eyes of others.

What needs to be done to address this problem?

Kate: It's essential that youth with HIV have access to stable housing so that they can consistently participate in health care and support services, eat nutritionally sound meals, get adequate amounts of rest, and avoid the daily stress of trying to find somewhere safe to sleep. The current New York City policy of restricting HIV/AIDS Services Administration (HASA) housing to people with an AIDS diagnosis greatly affects young people, since they are usually recently infected. This policy forces them to remain homeless until factors related to their homelessness interfere with their treatment to such an extent that they develop AIDS and are finally eligible for HASA housing.

Carl: Efforts to provide care for HIV-positive youth work best with a full range of services, so the program is not stigmatized as HIV-specific. Homeless LGBT youth are at such high risk of HIV infection because of the catastrophic merging of risk factors that homelessness adds to their lives. Addressing their homelessness is an important first step toward HIV testing and care. The terrible lack of safe and appropriate emergency housing for homeless LGBT youth is a public health crisis that we must address if we ever hope to stem the spread of HIV.

http://www.thebody.com
  more... []

Crazy ’House’
A panel discussion about a controversial AIDS documentary, House of Numbers, descended into a screaming match April 21 at the Boston International Film Festival, with both the film’s director, Brent Leung, and other members of the audience shouting down and attempting to drown out the remarks of Dr. Daniel Kuritzkes, an HIV expert and Harvard Medical School professor who was interviewed in the film.

April 22, 2009

house


Dr. Daniel Kuritzkes (second from left), a professor at Harvard Medical School, told the audience at the screening that Leung’s film gave unwarranted credibility to the AIDS denialist movement, and he accused Leung of taking his own comments out of context in the film. Kuritzkes was joined by fellow panelist and Fenway Health President and CEO Stephen Boswell (left), as well as (right to left) Liam Scheff and Christopher Fiala, two audience members who sat at the table uninvited and claimed that they were providing balance to the panel. (Source:Marilyn Humphries)

A panel discussion about a controversial AIDS documentary, House of Numbers, descended into a screaming match April 21 at the Boston International Film Festival, with both the film’s director, Brent Leung, and other members of the audience shouting down and attempting to drown out the remarks of Dr. Daniel Kuritzkes, an HIV expert and Harvard Medical School professor who was interviewed in the film.

Many of the audience members who attempted to silence Kuritzkes were supporters of a fringe movement known as AIDS denialism, which consists of people who argue that the HIV virus either is not the cause or not the sole cause of AIDS. While AIDS denialism has been roundly rejected as bogus science by the mainstream scientific and medical community, House of Numbers suggests that there is still a robust debate about the cause of AIDS, the existence of HIV, and the validity of HIV testing. Kuritzkes used his remarks to try to debunk the denialist movement, and he is one of more than a dozen scientists interviewed in the film who have signed onto a statement rejecting AIDS denialism and claiming that they were misled about Leung’s intentions in making the film.

Leung and the denialists in the audience at the AMC Loews Boston Common theater vocally objected to the format of the panel discussion even before it got underway. The panel, organized by Amit Dixit -- a board member of Massachusetts Area South Asian Lambda Association (MASALA) -- in conjunction with Fenway Community Health and the festival organizers, included Kuritzkes and Fenway president and CEO Dr. Stephen Boswell. Kevin Cranston, head of the Massachusetts Department of Public Health’s Bureau of Infectious Disease, served as moderator, and Cranston invited Leung to participate as a panelist, although Leung elected to remain in the audience.

As Kuritzkes began reading from a prepared statement two members of the audience who appeared in the film walked down to the front of the theater, sat beside Boswell and Kuritzkes at the panelists’ table and refused to leave. Those audience members, Christian Fiala, an Austrian gynecologist, and Liam Scheff, identified in the film as a freelance journalist, both claimed that they were forcibly joining the panel to provide balance. In the middle of Kuritzkes’s speech Leung and several other audience members shouted over him, "This is not a panel!" and, "Where’s the panel?" The shouting reached a fever pitch when Kuritzkes began reading a list of names of AIDS denialists who allegedly died of complications from AIDS.

"This is an exercise in free speech," said Cranston, attempting to quiet the crowd. "Dr. Kuritzkes is speaking. After he has completed speaking we will open up for free dialogue. We can only do this if one person speaks at a time. Shouting people down is not dialogue."

Several audience members continued shouting over Kuritzkes’s remarks despite Cranston’s admonition. Cranston warned audience members that anyone who continued to interrupt the program would be asked to leave. A police officer was present inside the theater, but he did not directly intervene, and Fiala and Scheff remained seated at the panelists’ table for the rest of the program.

Fair and balanced?

Leung’s film followed his personal journey to London, Germany, South Africa and the United States (Leung is Canadian) talking to a mix of scientists and health officials as well as AIDS denialist activists like Fiala, Scheff, and freelance journalist Celia Farber, who wrote a controversial 2006 article in Harper’s Magazine that was widely accused of promoting the denialist cause. The film included an interview with Peter Duesberg, a University of California-Berkeley molecular biology professor and arguably the most famous AIDS denialist. Leung also interviewed Christine Maggiore, founder of the denialist group Alive and Well. Maggiore was HIV-positive but denied the link between HIV and AIDS; she died last December. Maggiore’s supporters claim that her death was unrelated to AIDS, but a copy of her death certificate posted on AIDStruth.org, a site aimed at opposing the AIDS denialist movement, lists the cause of death as disseminated herpes viral infection and bilateral bronchial pneumonia, AIDS-related opportunistic infections. An L.A. Times obituary of Maggiore reports that her three-year-old daughter died in 2005 of AIDS-related pneumonia.

The film also included interviews with luminaries in the field of HIV/AIDS research, including Robert Gallo and Luc Montagnier, credited as co-discoverers of the HIV virus, Peter Piot, former executive director of UNAIDS, and Anthony Fauci, director of the National Institutes of Allergy and Infectious Diseases at the National Institutes of Health (NIH).

In his narration of the film Leung claims that his goal is to present an unbiased view of the state of HIV research, but his film suggests that certain key facts about HIV/AIDS that have been long settled in mainstream scientific circles are still in dispute. During a segment about the beginnings of the AIDS crisis among gay men in the United States Kary Mullis, a leading AIDS denialist and a Nobel Prize-winning chemist, blamed many early AIDS cases on poppers, saying, "What exactly caused Kaposi’s sarcoma? We know that now. It was amyl nitrite."

Former Sunday Times health reporter Neville Hodgkinson, who wrote several articles questioning the link between HIV and AIDS, says in the film, "The lifestyle explanation proved politically unacceptable, but the virus explanation proved very, very acceptable to many different parties."

In another section Duesberg claims that many of the symptoms of AIDS were in fact caused by the drugs used to treat the syndrome. Several people interviewed in the film question the effectiveness of HIV tests. Ostensibly to provide balance the film also includes interviews with people rebutting the AIDS denialists’ arguments, but there is minimal discussion of the reasons why mainstream scientists have largely written off the denialists’ claims as junk science. During one interview Duesberg says, "They’re all prostitutes, most of them, my colleagues."

At the film’s end Leung suggests that the cause of the global AIDS epidemic is poverty, not the HIV virus.

"At journey’s end I find myself perplexed, bewildered at times with an overall feeling of dismay and sadness. I found a research community in disarray over the most fundamental understanding of HIV, all the while presenting a monolithic public posture of authority and certainty. Bluntly stated, we have tests that prove nothing, remedies that kill, and statistics manipulated to the point of absurdity," Leung says. "Ninety percent of global HIV corresponds to areas of great poverty and squalor. Ironically, while we may have been pursuing a phantom killer, a shape-shifting assassin, perhaps the real enemy has been hiding in plain view, clear as day and as old as time."

During a post-film question-and-answer session held before the panel Leung claimed that his film took a neutral stance on the question of what causes AIDS. He declined to say which side he represents.

"The purpose of the film is to present a broad range of ideas, and those ideas are for you, the audience, and for scientists to take and to create a catalyst for more discussion," said Leung.

One audience member asked Leung who funded the film, noting that Leung seemed to have a large budget for travel. Leung declined to name the sources but described them as a group of "funders from all over the world." When Bay Windows later asked him if most of his funders supported the viewpoint of AIDS denialists, Leung claimed that they did not.

Filmmaker versus subject

Once the panel discussion got underway and Cranston succeeded in getting the audience under control, Elizabeth Ely, an audience member affiliated with the denialist group Rethinking AIDS, asked Kuritzkes what remarks in the film had been taken out of context. Kuritzkes said his own remarks in the film had been presented in a misleading light. During the film there is a brief clip of Kuritzkes saying that in the early days of the epidemic the standard dosage of the AIDS drug AZT was likely too high. The clip follows comments by Duesberg blaming AZT for many of the symptoms of AIDS.

"I can give you an example of my own quotation where I was quoted very briefly in talking about how early doses of AZT were toxic and that was the end of the statement, but in a broader discussion about anti-retroviral therapy, as I recall, the issue is really that the drugs have improved over time, the drugs have become less toxic, and the treatments today are highly effective, which is why we’ve seen an 80 percent reduction in mortality from HIV," said Kuritzkes.

Leung jumped in and told the crowd, "I would like to add that was not taken out of context. Antiretrovirals are a separate part of the film. AZT is one part of the film."

Kuritzkes replied, "AZT is an antiretroviral, unfortunately."

Kuritzkes is one of several scientists featured in the film who have since come forward and argued that they were interviewed for the film under false pretenses and that they believe House of Numbers promotes an AIDS denialist agenda. John Moore, a professor at Weill Medical College of Cornell University, drafted a statement signed by himself and 15 others interviewed for the film, including Kuritzkes, Gallo and Piot, alleging that the film "presents the AIDS denialist agenda as being a legitimate scientific perspective on HIV/AIDS, when it is no such thing. [Leung’s] film perpetuates pseudo-science and myths."

Moore, who was not present at the screening, told Bay Windows he and several other scientists interviewed for the film first came in contact with Leung through Martin Delany, the pioneering AIDS activist and executive director of Project Inform who passed away in January. Delany was interviewed for the film, and Moore said Delany vouched for Leung as a legitimate filmmaker. Moore said Leung interviewed him on two successive occasions, once in 2006 and again a year later, and said Leung told him the goal of his film was to document the history of AIDS research and to expose the lies behind the denialist movement. Several weeks ago Moore said Leung e-mailed him and other film participants a link to the film trailer, and Moore was shocked to find that the film seemed to present a sympathetic portrait of denialists.

"I didn’t know he lied until I saw the trailer," said Moore, who said watching the trailer prompted him to draft his statement and contact the other film participants to ask them to sign it. He has not seen the film, which debuted at the Nashville Film Festival April 19 and has only screened in Nashville and Boston, but he said based on the trailer and conversations he has had with people who have attended the screenings he believes the film falls squarely in the denialist camp.

Leung told Bay Windows that he was up front with Moore about the subject of his film. He said he told Moore that the film was a documentary on public awareness about HIV and AIDS, about AIDS education and testing and other issues relating to the epidemic. He also said that since Moore had authored a 2006 New York Times op-ed opposing the denialist movement entitled "Deadly Quackery," he wanted "to address whether HIV is the cause of immune deficiency. And that was the extent that I told him it was about." He said he believes some of the scientists who signed Moore’s statement were upset because the film allegedly shows them making contradictory statements about the nature of HIV and AIDS.

What’s at stake

During the panel discussion Boswell told the denialists in the crowd, "It’s important to know there’s a lot at stake. If you’re wrong and HIV does cause [AIDS] you’re doing a profound disservice to our race."

Ely responded from the audience, saying, "And if you’re wrong you’re doing a profound disservice. That’s our point."

Boswell replied, "Science has a way, a system for testing new ideas, and if you have an idea that’s different then you can present those ideas, you can test them in a scientific way, present your findings in a peer-reviewed journal, have another laboratory verify what you say happened. I haven’t seen any of that happen in any of this work. All I know is that we test for HIV in the blood supply and over a period of three years transfusion-transmissible AIDS virtually disappeared in the United States. We start testing women for the HIV virus who are pregnant, and we virtually eliminate AIDS in children. In 1995 I give a cocktail of medications to patients who are within weeks of dying, and those patients a few weeks later have gained 10, 20 pounds, and some of them are alive today."

Following the panel Leung told Bay Windows that he nearly pulled the film from the festival 15 minutes before the screening. He said festival organizers had promised him that there would be a "two-sided" panel discussion, and he objected to the selection of Cranston as moderator, calling him "obviously biased to one side" because of his work on HIV/AIDS in the public health sector.

Asked if his film was designed to spread the message of the AIDS denialist movement Leung said, "I don’t feel strongly about getting their message out. I feel strongly about freedom of speech. As I’ve gone around the world interviewing these world scientists who set the foundation for everything we know about HIV and AIDS and continue to set the foundation in policies, I found that there’s a lot of disconnect between what they say, there’s a lot of contradiction, there’s a lot of confusion, and people are dying. So it doesn’t matter who says what, what arguments come from each side. We have to have an open dialogue. We need to know why people are dying."

The film festival released a statement saying that the goal of the post-film panel was to create a venue for members of the community to respond to the film.

"The Boston International Film Festival never intended to host a formal debate about the film; we intended to provide a forum in which members of the community could engage with, and respond to, the film. It was a difficult decision to screen ’House of Numbers,’ and we are very pleased that the director, Brent Leung, attended the screening and answered questions about his film," read the statement in part.

The statement goes on to say that there was some miscommunication between festival organizers and the filmmaker about the format of the panel discussion but that the festival decided to go forward with the panel "to create an opportunity for healthy social discourse."

The statement also says the festival requested the presence of a police officer at the screening in response to concerns about security.

"In anticipation of the event, we were concerned about security and we believed it was very important to have a visible police presence at the screening; Security issues were also considered in how the situations were handled. ...We are issuing this statement so that other festivals can be aware of the potential for escalated actions, and that the other festivals can be extremely diligent in their planning so that future screenings can be executed in a safe and constructive manner."

Chloe McFeters, public relations manager for the festival, declined to elaborate on what prompted concerns about security. Dixit, who worked with the festival organizers to organize the panel discussion, said the festival requested a police officer because an AIDS denialist with a past history of violent actions and run-ins with the law had posted on the Internet that he would attend the Nashville screening, and the Boston festival organizers were concerned he would attend the Boston screening as well.

Dixit said that he believes the film presents a biased perspective in favor of the AIDS denialists, and the goal in selecting Boswell and Kuritzkes as the panelists was to bring in respected members of the local scientific community to present their response to the claims laid out in the film.

"I said [to the filmmakers during the planning process] you have 87 minutes, and then the director Q&A, but for me to put these people on the same panel [the night of the screening] who barged up, who have no credentials, it’s an absolute insult to the people we know, it’s an insult to Boswell and Dan who have been doing this for years. ... Fenway, myself, we were about creating a scientific dialogue, that was what the whole premise was," said Dixit.

He said he was frustrated that the denialists in the audience seemed intent on drowning out the panelists.

"For me I was very disappointed in not being able to hear the experts. Dan spoke eloquently and he answered the questions right on. I was very proud to have our heroes onstage," said Dixit. "But I was very disappointed. What we tried to do was create a scientific dialogue. It was interrupted by denialists in the audience who were very aggressive, and they couldn’t engage in a civil manner to our experts."

By Ethan Jacobs, http://www.baywindows.com
  more... []

Curb Aids and HIV by decriminalising drugs, say experts
In an unprecedented attack on global drugs policy, Michele Kazatchkine, head of the influential Global Fund to Fight Aids, Tuberculosis and Malaria, has told the Observer that, without a radical overhaul of laws that lead to hundreds of thousands of drug users being imprisoned or denied access to safe treatment, the millions of pounds spent on fighting HIV and Aids will be wasted.

April 19, 2009

map

Aids and HIV worldwide. Photograph: Cat Davison/Pete Guest

The use of illicit drugs must be decriminalised if efforts to halt the spread of Aids are to succeed, one of the world's leading independent authorities on the disease has warned.

In an unprecedented attack on global drugs policy, Michele Kazatchkine, head of the influential Global Fund to Fight Aids, Tuberculosis and Malaria, has told the Observer that, without a radical overhaul of laws that lead to hundreds of thousands of drug users being imprisoned or denied access to safe treatment, the millions of pounds spent on fighting HIV and Aids will be wasted.

Kazatchkine will use his keynote speech at the 20th International Harm Reduction Association conference tomorrow in Bangkok to expose the failures of policies which treat addiction as a crime. He will accuse governments of using what he calls "repressive" measures that deny addicts human rights rather than putting public health needs first.

He will argue that governments should fully commit to the widespread provision of harm reduction strategies aimed at intravenous drug users, such as free needle exchanges and providing substitutes to illicit drugs, such as methadone.

"A repressive way of dealing with drug users is a way of facilitating the spread of the [HIV/Aids] epidemic," Kazatchkine said. "If you know you will be arrested, you will not go for treatment. I say drug use cannot be criminalised. I'm talking about criminalising trafficking but not users. From a scientific perspective, I cannot understand the repressive policy perspective."

He condemns policymakers who argue that, because drug users frequently turn to crime to fund their habit, it justifies making it a criminal justice issue. Harm reduction both helps the addict and wider society and reduces the need to commit crime, he said.

"The one population where [Aids] mortality has been untouched - and in fact has worsened - has been IV [intravenous] drug users. It's amazing, because what we call harm reduction, such as exchanging needles, has been scientifically proven as the most effective.

"This is why I will most probably start my speech in Bangkok by mentioning the contrast between major progress achieved in decreasing mortality from Aids in the poorest countries of the world versus the total lack of progress for what is the main route of transmission in most parts of the world outside Africa."

Kazatchkine suggested that politicians feared that the public would label them soft on drugs. A doctor and respected Aids expert with 20 years in the field, he has in his two years at the helm of the Global Fund overseen some of the most dramatic improvements in treatment and prevention of HIV globally.

Since it was established in 2001, the fund has received $21bn in contributions from the world's wealthiest nations and used it to play a significant part in reducing rates of new HIV infections. It has also contributed to the distribution of much needed life-preserving anti-retroviral drugs to millions of people already diagnosed.

Alex Stevens, a senior research fellow specialising in drugs and criminalisation at the University of Kent, said tomorrow's speech would highlight many of the troubling consequences of criminal justice approaches to drugs policy.

"In many countries, serious human rights infringements are committed in the name of fighting drugs," he said. "These include the use of the death penalty for drug offences, compulsory treatment regimes that include methods (such as physical beatings) that are akin to torture, and, for example in the USA, depriving convicted drug law offenders of the right to vote."

Stevens said that, while the UK was ahead of many other countries on harm reduction, its tendency to criminalise drug users could undermine its efforts.

What is needed, Kazatchkine will argue tomorrow, is a total rethink of drugs policies. "What I'm saying is that government's function is to protect their citizens. This is why harm reduction should be supported by all governments everywhere."

by Mary O'Hara with Additional research by Ali Ahmad, http://www.guardian.co.uk

  more... []

Brits with HIV 'still being refused entry to US"
Terrence Higgins' Trust states it has received calls from people who used the online visa system and believed they were permitted to travel but were turned away at US border controls, incurring substantial travel expenses. Lisa Power, head of policy at THT, said: “While we are pleased that the US government intend to revisit their entry regulations, it has not happened yet.

April 20, 2009


passport
Those with HIV have been warned they must ensure
they are legally allowed to travel

People living with HIV are still being refused entry to the US, despite government plans to change legislation, it has been claimed.

According to the Terrence Higgins Trust (THT), those with HIV who want to travel to the US must attend an interview at the American Embassy in London before they can travel legally.

A new online visa waiver system was set up recently, but those who have HIV must still have a special visa.

Currently, people with HIV are permanently excluded from the United States except in exceptional circumstances.

Following new legislation last year, the HIV entry ban is no longer law, but remains an administrative decision to be ruled on by the Department for Health and Human Services.

THT states it has received calls from people who used the online visa system and believed they were permitted to travel but were turned away at US border controls, incurring substantial travel expenses.

Lisa Power, head of policy at THT, said: “While we are pleased that the US government intend to revisit their entry regulations, it has not happened yet.

"People with HIV shouldn't jump the gun by assuming it's already okay to travel to the US without a special visa.

"Everyone entering the US is still required to state that they have no transmissible conditions, alongside not being a terrorist, a Nazi or a criminal.

"People who don’t get the special visa but then disclose their status on entry run the risk of being forcibly deported and banned from entering the US again, so please be aware of the rules before you fly.”

People living with HIV who would like further information on their right to travel internationally can contact THT Direct on 0845 1221 200 from 10am to 10pm weekdays and from 12pm to 6pm weekends, or email info@tht.org.uk.

Related Articles
HIV stigma "fuels homophobia and discrimination"
HIV rates in gay men still at high levels
One-third of HIV sufferers 'face discrimination'
Gay men in Jamaica 'face higher levels of HIV due to discrimination'

http://www.pinknews.co.uk
  more... []

Female Condom Approval Raises Hopes for Global Use
An early version of the female condom was introduced in 1993, and it remains the only available woman-initiated form of protection against both STDs and unintended pregnancy. Yet despite global promotion by the United Nations and other organizations, its usage is still minuscule, even as women bear an ever-growing share of the AIDS epidemic. Advocates hope the dynamics will change following last month's approval by the Food and Drug Administration of the FC2, a new version of the female condom produced by Chicago-based Female Health.

April 20, 2009

condom
Advocates of the female condom are promoting a less costly,
more user-friendly version that they hope will vastly expand its role in the global fight
against HIV and other sexually transmitted diseases.

RELATED ARTICLES
FDA Approves Female Condom
Advocates Tout Female Condoms
Women Demand Access to Female Condoms

An early version of the female condom was introduced in 1993, and it remains the only available woman-initiated form of protection against both STDs and unintended pregnancy. Yet despite global promotion by the United Nations and other organizations, its usage is still minuscule, even as women bear an ever-growing share of the AIDS epidemic.

Advocates hope the dynamics will change following last month's approval by the Food and Drug Administration of the FC2, a new version of the female condom produced by Chicago-based Female Health.

About 35 million female condoms were distributed worldwide last year, but that compares to more than 10 billion male condoms, which are far cheaper and, at least initially, easier to use. However, in some nations with high HIV rates, many men refuse to wear condoms, putting women at risk.

Though it looks similar to its predecessor -- a soft, transparent sheath with flexible inner and outer rings -- the FC2 is made from synthetic rubber rather than polyurethane, making it cheaper to produce.
Mary Ann Leeper, former president of Female Health and now its strategic adviser, said the FC2 also is less noisy during use. Complaints about squeaky noises were among the factors that slowed acceptance of the original version.

The cost of the FC2 is one third less than its predecessor, and may go lower, enabling health organizations to distribute many millions more than at present. For now, the price is about 60 cents, compared to less than 4 cents for mass-distributed male condoms -- a difference that's an issue in the developing world.

The FC2 had been accepted previously by some international organizations, and Female Health distributed 14 million of them abroad last year along with 21 million of the older version. Advocates of the female condom praised the FDA announcement because it opens the door for the U.S. Agency for International Development (USAID), one of the largest global providers of condoms, to distribute the FC2 overseas.

"This is a tremendous victory," said Susie Hoffman, an assistant professor of clinical epidemiology at Columbia University who contends the female condom has suffered from misconceptions. "In the United States, there has been strong bias against it," Hoffman said. "Some people involved in AIDS and family planning would say, 'Why do we need these? ... It's so weird that women are not going to pick it up.' But if presented in the right way, many women do like it. To find these people and help them and train them, you need systematic programming, which costs money."

Resistance is less of a problem in some developing nations. The United Nations Population Fund, government agencies, and nonprofits are aggressively promoting female condoms in places such as Brazil, Ghana, Zimbabwe, and South Africa.

Women's groups in Zimbabwe collected more than 30,000 signatures demanding access to the female condom. In Ghana, nonprofits say more than 10,000 people have attended training programs that teach women how to insert female condoms -- they require careful instruction to be used properly -- and how to negotiate with their male partners.

"The mind-set is changing, but there are still a lot of challenges," said Bidia Deperthes, the Population Fund's HIV technical adviser for condoms. "Accessibility is still minimal. There's a huge demand, and we're not meeting it."

Deperthes hopes that with FDA approval of the FC2, the number of female condoms distributed globally could climb to 50 million this year. If the numbers keep rising, she said, the cost to public-sector distributors for each FC2 could drop as low as 25 cents.

Jeff Spieler, a science adviser with USAID's Office of Population and Reproductive Health, said the female condom's future may depend on whether its promoters can develop a private-sector market. Its commercial price in the United States generally has been more than $2.

Another challenge is a stigma associated with the female condom in some places because prostitutes are among those deemed to benefit most from using it. On the other hand, advocates of the female condom say it has invaluable safer-sex potential for married women whose husbands are unfaithful and shun male condoms.

Serra Sippel, executive director of the Center for Health and Gender Equity in Washington, D.C., said the FDA approval of the FC2 is a key step toward "putting the power of prevention in women's hands." But she bemoaned the product's limited over-the-counter availability. “We'd love to see the profile raised, to have commercials about it and normalize it so people aren't embarrassed," she said.

Mary Ann Leeper said Female Health is seeking a corporate partner to help market the FC2. She suggested that concern about HIV may generate interest among women in communities with high infection rates.

The female condom's advocates stress that it will never be the "magic bullet" that by itself turns the tide in fighting AIDS. But, they say, it should be a bigger part of the arsenal.

"It's not going to be the one answer," Hoffman said. "But it's got a lot more to contribute than it has to date.”

[This report reprinted with permission of the Associated Press. (c) 2009 by Associated Press | David Crary | April 16, 2009]

http://www.hivplusmag.com
  more... []

German AIDS Group Endorses HIV Treatment as Prevention
A premier German nongovernmental organization (NGO) is endorsing antiretroviral medication as an effective form of HIV prevention, mirroring last year’s Swiss statement on the lowered risk of transmission from positive people on treatment to their negative partners, aidsmap.com reports.

April 22, 2009

A premier German nongovernmental organization (NGO) is endorsing antiretroviral medication as an effective form of HIV prevention, mirroring last year’s Swiss statement on the lowered risk of transmission from positive people on treatment to their negative partners, aidsmap.com reports.

Researchers from the Swiss Federal Commission for HIV/AIDS said that HIV-positive people on meds and with undetectable viral loads for six months and no sexually transmitted infections (STIs) cannot transmit the virus through heterosexual sex.

According to the article, Deutsche AIDS-Hilfe calls transmission in such circumstances “unlikely” and claims that antiretroviral treatment is as effective as condom use in preventing infection in negative partners.

In a position paper, Deutsche AIDS-Hilfe says that sexual HIV transmission is unlikely when the HIV-positive partner’s viral load has been undetectable for at least six months, the person is adhering to antiretroviral therapy and there is no damage to the mucous membranes.

In those circumstances, the NGO says, the risk of transmission is negligible and, when combined with condom use, is close to zero.

http://www.poz.com

  more... []

STUDIES  & TREATMENT  eNEWS

Significant reductions in price of first- and second-line HIV treatment thanks to UNITAID and Clinton deal
HIV treatment consisting of just one pill, once a day, will be available in poorer countries at a cost of $210 per patient, per year, thanks to an agreement announced by UNITAID and the Clinton HIV/AIDS Initiative.

April 17, 2009

HIV treatment consisting of just one pill, once a day, will be available in poorer countries at a cost of $210 per patient, per year, thanks to an agreement announced by UNITAID and the Clinton HIV/AIDS Initiative. The price of boosted protease inhibitor-based second line HIV treatment will also falls significantly to an annual cost per patient of $590.

Deals were struck by UNITAID and the Clinton Initiative with generic manufacturers to enable these price cuts. Thanks to the deals there is a 17% reduction in the price of the most affordable second-line antiretroviral combination of 3TC, tenofovir and ritonavir-boosted lopinavir for the world’s poorest countries. Heat-stable lopinavir/ritonavir will be available at a maximum cost of $470 per patient, per year. Generic versions of atazanavir and heat-stable ritonavir are expected to yield further price decreases. UNITAID funded projects in 42 poorer countries will benefit from the reductions in the cost of second-line treatment. They will also be available to over 70 developing countries that are members of the Clinton HIV/AIDS Initiative’s Procurement Consortium, as well as being extended to participants in the Global Fund’s Voluntary Pooled Procurement scheme.

More tolerable and convenient first-line HIV treatment will also become more affordable thanks to new price agreements. A single pill that combines HIV treatment consisting of 3TC, tenofovir and efavirenz in a single pill taken once a day will be available for an annual per patient cost of $210. This price compares with a maximum cost of $89 a year for a fixed dose combination of d4T, 3TC and nevirapine, which is taken twice daily. This represents a reduction of 30% on prices agreed by UNITAID and the Clinton Initiative in 2008, and is over a third lower than the average cost of this combination in low-income countries.

The latest agreements between UNITAID and the Clinton initiative will bring down the price of 41 adult and paediatric formulations of anti-HIV drugs. The new prices are on average 16% lower than the lowest prices in 2008. Since 2007 UNITAID and Clinton deals have helped bring about a 62% reduction in the price of first-line HIV therapy for the world’s poorest countries hardest hit by HIV. Price reductions for second-line treatment are projected to bring annual savings of $100 million.

By Michael Carter, http://www.aidsmap.com

  more... []

“Quad” HIV Pill Enters Phase II Study
Gilead Sciences Inc. announced today it initiated a Phase II study of a new four-in-one—or “Quad”—HIV treatment. The Quad pill includes Gilead’s experimental integrase inhibitor called elvitegravir, an experimental boosting agent called GS 9350 and the approved drugs Viread (tenofovir) and Emtriva (emtricitabine).

April 20, 2009

Gilead Sciences Inc. announced today it initiated a Phase II study of a new four-in-one—or “Quad”—HIV treatment. The Quad pill includes Gilead’s experimental integrase inhibitor called elvitegravir, an experimental boosting agent called GS 9350 and the approved drugs Viread (tenofovir) and Emtriva (emtricitabine).

The study will enroll 75 HIV-positive people who’ve never taken antiretroviral therapy before and will randomize them to take either the Quad pill or Atripla (efavirenz, tenofovir and emtricitabine). The 48-week trial will determine both the efficacy and the safety of the Quad pill after 24 and 48 weeks of treatment.

The study is not so much to evaluate the efficacy and safety of elvitegravir—which has already successfully completed a Phase II study and is now in two large Phase III studies—as much as to test the new blood level boosting agent GS 9350, which is being examined as an alternative for low-dose Norvir (ritonavir).

http://www.poz.com

  more... []

CD4 cell counts becoming lower soon after infection with HIV, suggests virus becoming more virulent
“We observed that initial CD4 cell count among documented HIV seroconverters in the United States significantly decreased during the HIV epidemic,” write the investigators. This decline reached a plateau after the use of antiretroviral therapy became widespread. The investigators speculate that the fall in initial CD4 cell counts was likely to be because HIV had evolved to become more virulent.

April 21, 2009

The initial CD4 cell counts of patients newly infected with HIV fell significantly between 1985 and 2001, US research published in the May 1st edition of Clinical Infectious Diseases has shown. This suggests that the virus may have evolved to become more virulent during this time period, which could have clinical implications, shortening the interval between infection with HIV and the need to start HIV treatment.

In people with HIV, CD4 cell counts provide an important indication of the strength of the immune system, of HIV disease progression and of when to start antiretroviral treatment.

At the time of HIV infection a massive loss of CD4 cells occurs. The immune system then mounts a response to HIV, virus levels fall, and the CD4 cell count recovers - although often it fails to return to levels seen in healthy individuals. The CD4 count soon after infection with HIV is a strong indicator of the subsequent risk of disease progression: in cases where the CD4 count stabilises at a level below 350, an individual has a higher short-term risk of disease progression.

It is generally assumed that there will be an interval of several years between initial infection with HIV and a fall in CD4 cell count to such levels that the initiation of HIV treatment is warranted. However, there is some evidence in recent years of patients having lower CD4 cell counts shortly after their infection with HIV, and of more rapid disease progression, requiring HIV treatment soon after diagnosis.

US investigators therefore analysed the initial CD4 cell counts of patients recently infected with HIV between 1985 and 2007. The study population was racially diverse and came from HIV treatment centres across the country.

A total of 2174 people were included in the investigators’ analysis. All had had an HIV-negative test result at most four years before their diagnosis with HIV.

The mean age was 29 years; 96% were men; 45% were African American, 44% white and 11% other ethnicities.

Just over a third (35%) were diagnosed with HIV within a year of a previous negative test result, 41% were diagnosed within one to two years of testing HIV-negative, 17% within two to three years, and 7% within three to four years. A CD4 cell measurement was taken within three months of HIV diagnosis in 90% of patients.

Changes in initial CD4 cell count were examined in four separate time periods: 1985 to 1990; 1991 to 1995; 1996 to 2001; and 2002 to 2007.

Between 1985 and 1990, the mean initial CD4 cell count of individuals recently infected with HIV was 632 cells/mm3. This fell to a mean of 553 cells/mm3 for the period 1991 and 1995, and to a mean of 493 cells/mm3 between 1996 and 2001. The figure then stabilised at a mean of 514 cells/mm3 between 2002 and 2007.

The fall in initial CD4 cell count between the period 1985 and 1990 and 1991 to 1995 was highly significant (p < 0.001), as was the fall between this period and 1996 and 2001 (p < 0.001).

Further analysis showed that the proportion of individuals with an initial CD4 cell count below 200 cells/mm3 (an AIDS diagnosis), and 350 cells/mm3, the point at which it is now recommended to start antiretroviral therapy, increased significantly between 1985 and 2001.

The investigators then conducted statistical analysis to control for possible confounding factors. This showed that compared to the period 1985 to 1990, initial CD4 cell count was 65 cells/mm3 lower in the period 1991 to 1995 (p < 0.001), 107 cells/mm3 lower in the period 1996 to 2001 (p < 0.001) and 102 cells/mm3 lower in the period 2002 to 2007 (p < 0.001).

Similar declines were observed in initial CD4 cell percentage: from 30% in the period 1985 to 1990 to 28% between 1991 and 1995, and 27% in both the later time periods. Adjusted analysis showed that these falls in CD4 cell percentage were significant in all time periods.

Finally the investigators analysed the possible effect of race on their results. They found that in both African-American and white patients initial CD4 cell count declined by a mean of 111 cells/mm3.

“We observed that initial CD4 cell count among documented HIV seroconverters in the United States significantly decreased during the HIV epidemic,” write the investigators.

This decline reached a plateau after the use of antiretroviral therapy became widespread. The investigators speculate that the fall in initial CD4 cell counts was likely to be because HIV had evolved to become more virulent.

Reference
Crum-Cianflone N et al. Is HIV becoming more virulent? Initial CD4 cell counts among HIV seroconverters during the course of the HIV epidemic: 1985 – 2007. Clin Infect Dis 48: 1285-1292, 2009.

By Michael Carter, http://www.aidsmap.com

  more... []

Isentress’s Prevention Potential
The integrase inhibitor Isentress (raltegravir), when taken by either HIV-negative or HIV-positive people, might be able to prevent HIV transmission, according to a presentation at the International Clinical Pharmacology Workshop in Amsterdam.

April 21, 2009

The integrase inhibitor Isentress (raltegravir), when taken by either HIV-negative or HIV-positive people, might be able to prevent HIV transmission, according to a presentation at the International Clinical Pharmacology Workshop in Amsterdam.

Though Viread (tenofovir) and Truvada (tenofovir plus emtricitabine) are the leading antiretroviral (ARV) treatments being tested for use in HIV-negative people to prevent HIV infection, other ARVs are being considered for pre-exposure prophylaxis (PrEP). Researchers have also begun studying whether treating HIV-positive people, regardless of their CD4 count or medical need for ARV therapy, might help them reduce the risk of transmitting HIV to their HIV-negative partners.

One of the primary questions with using a specific ARV with either strategy is how well the drug reaches and accumulates in the genital tract compared with the blood stream. Researchers speculate that if an HIV medication does not easily penetrate the genital tract—the initial site of infection for many exposed to the virus and a reservoir for HIV among those living with the virus—it may not be the best choice for prevention purposes.

To determine genital tract distribution with Isentress, Amanda Jones, PharmD, from the University of North Carolina in Chapel Hill, and her colleagues studied blood and genital levels of Isentress in seven HIV-negative women. All of the women took Isentress twice daily for six days and once in the morning on the seventh day. They began taking their first dose between five and seven days after completing their last menstrual period.

Jones’s team found that Isentress levels took longer to build up in the genital tract following the first dose than in the blood, but after multiple doses Isentress levels stayed 93 percent higher in the genital tract than in the blood. This is lower than a few drugs such as Selzentry (maraviroc), which reaches genital levels more than 400 percent higher than in blood, but roughly comparable with Viread. What’s more, Isentress levels lasted nearly two and a half times longer in the genital tract than in blood.

The authors suggest that Isentress might be a promising candidate for PrEP. They also state that HIV-positive people who take Isentress might be less likely to pass HIV on to others through sexual contact due to high concentrations of the drug in the genital tract.

http://www.aidsmeds.com
  more... []

THE AIDS ANNIVERSARY

Taming a deadly disease
There is still no vaccine and no cure, but 25 years after AIDS was discovered, sufferers are no longer dying from the virus

April 22, 2009

Twenty-five years after the discovery of the AIDS virus, the deadly disease has been halted in its tracks – so much so that sufferers are now dying at a ripe old age.

Nearly 85 per cent of patients being treated for HIV-AIDS with drug cocktails have undetectable levels of virus in their bloodstream, according to new data from the B.C. Centre for Excellence in HIV-AIDS in Vancouver.

“People with HIV are not exempt from destiny,” Dr. Julio Montaner, the centre's director, said in an interview, “but they are no longer dying from AIDS.” That fact, he said, “really tells the story of how far we've come with treatment.”

When Margaret Heckler, then secretary-general of the U.S. Health and Human Services Department, announced at a Washington news conference on April 23, 1984, that the “probable cause” of AIDS had been found, she boldly predicted a vaccine within two years and eradication of the disease by 1990.

pic
Toronto activist Ron Rosenes
has been living with HIV for more than 25 years.
(Charla Jones/The Globe and Mail)

Related Articles
Recent
The greying of AIDS:
Profiles of Canadians who have been living with the disease for decades.
GLENN FASH, 59

LYNN KAMPF, 58
JOHN KOZACHENKO, 53
FERNANDO RODRIGUEZ, 46

If only it were so.

There is still no vaccine, no cure, and HIV-AIDS continues to spread relentlessly, with 2.7 million new infections worldwide last year and 33 million people living with the virus.

The good news is that scientists have learned to subdue the wily human immunodeficiency virus: Powerful drug combos are used to shut down HIV replication and limit the damage it inflicts on the immune system.

The impact of this treatment regime, known formally as highly active antiretroviral treatment (HAART), is undeniable – adding, on average, 13 years to the life expectancy of HIV-positive people, according to a study by Robert Hogg of the B.C. Centre for Excellence in HIV-AIDS.

Virtually anyone with money – or access to a public-health system like Canada's – can neutralize the virus's effects on the immune system and have a normal life expectancy.

“There's no reason people can't live 50 years with HIV,” said Anita Rachlis, an infectious-diseases consultant at Sunnybrook Health Sciences Centre in Toronto. “But people with HIV often have a lot of co-morbidities.”

Indeed, while survivors are living longer, they are also dealing with a combination of related health challenges: the ravages inflicted on the immune system by the virus over many years; the damage done by long-term use of powerful drugs; and the effect of other infections that came along for the ride with HIV (such as hepatitis, herpes and HPV), not to mention the normal process of aging.

“I wonder what's going to get me, but I don't think it's going to be AIDS,” said Ron Rosenes, a Toronto activist who has been living with HIV since the early days of the epidemic. Rather, he worries about anal cancer, lymphoma and heart disease – which are common in long-time survivors because of immune-system damage.

Like most Canadians with HIV-AIDS, Mr. Rosenes takes a cocktail of three drugs to keep the virus in check. He also takes medication to deal with some of the side effects, including drugs for osteoporosis and acid reflux, and a powerful vitamin and mineral supplement called K-PAX to bolster his immune system. “I never thought I would live to 50, let alone 61,” Mr. Rosenes said.

There is, in fact, a growing legion of people reaching their golden years with what was once a disease of the young.

“Treatment advances have transformed HIV from a death sentence to a life sentence,” said Bill Cameron, president-elect of the Canadian Association for HIV Research.

Dr. Cameron said medications have evolved over time. At first they were used to control infections, then drugs were combined to suppress the virus, and now those drugs are being refined to be less toxic and better tolerated.

Years ago, it was not uncommon for AIDS sufferers to take 40 to 50 pills a day on complex timetables. These drugs would often cause severe diarrhea and lipodystrophy – the abnormal distribution of fat – that left people with buffalo humps on their backs, grossly distended bellies and hollowed-out cheeks.

Today, many people can manage HIV-AIDS with a single daily pill with no visible side effects.

A bigger challenge than the treatment itself is getting people tested and into treatment. Approximately 62,000 people in Canada are living with HIV-AIDS, and about one-quarter of them are unaware of their HIV status, the Public Health Agency of Canada says.

According to the agency, men who have sex with men continue to make up the largest chunk of newly infected people at 43 per cent, while heterosexuals comprise another 25 per cent. Intravenous drug users account for 20 per cent of new infections, and immigrants from countries where AIDS is endemic account for 7 per cent. (The balance is made up of people whose history of exposure to the virus is unclear.)

“AIDS is increasingly a social disease. It's associated with disenfranchised people,” Dr. Cameron said. These groups can be hard to reach so they often do not benefit from treatment advances.

While the pace of improvements in treatment and care can seem glacial to those who are sick, the speed at which the virus that causes AIDS was discovered, treatments developed and then widely used in the clinical setting (at least in wealthy countries like Canada) is unprecedented.

The virus was discovered in 1984; the first treatment, zidovudine (AZT), was on the market in 1987. Triple cocktails made their debut in 1996, and by 2006 there was a once-a-day pill. This happened in large part because activists – gay men, victims of tainted blood and scientists – pushed governments relentlessly to fund research. Those with HIV-AIDS also offered themselves up as guinea pigs in clinical trials. Most of the long-time activists are long-time survivors.

Janet Conners is a case in point.

The 53-year-old Halifax resident was for many years a public figure, a woman who had contracted HIV from her hemophiliac husband who had been infected by tainted blood products, and she fought tirelessly for justice and compensation. But the disease took its toll: Ms. Conners lost her husband to AIDS, becoming a widow at 37, struggled with the effects of immune deficiency and of treatment, and, in 2001, had a serious heart attack.

“These drugs have kept me alive but you have to understand this is chemotherapy. It's hard on the body and on the mind,” she said.

Like many long-term survivors, Ms. Conners developed resistance to some medications, so she required increasingly powerful substitutes. She is now on “salvage therapy” – meaning she is running out of treatment options.

In addition to heart problems, Ms. Conners suffers from neuropathy, the loss of feeling in her extremities, along with muscle loss and weakening bones. She takes upwards of 30 pills a day – the majority not for HIV any more. “My pill box is my full-time job,” she said. It is also a bittersweet mistress. “After 20 years of daily use, I have pill burnout.”

But, for all the challenges, the treatment still represents hope. Ms. Conners, who was given only a few years to live when she was diagnosed in 1989, has survived longer than she ever expected, has seen her son grow to adulthood, and has remarried.

“The meds are not a magic bullet,” she said. “But they've allowed me and many others to have a life.”

By Andre Picard, http://www.theglobeandmail.com
  more... []

British Columbia Persons With AIDS Society
1107 Seymour Street, 2nd Floor
Vancouver, BC V6B 5S8
Canada
[ Map ]
t. 604.893.2200
1.800.994.2437
f. 604.893.2251
www.bcpwa.org
info@bcpwa.org
Feel free to pass this along to those you feel will be interested.
To have the BCPWA eNews delivered to your inbox, click here [ Subscribe ].
If you no longer wish to receive the BCPWA eNews, click here [ Unsubscribe ].

The HIV / AIDS eNews is brought to you by the BCPWA's Communication Department.
Authorized by the Persons With AIDS Society of BC, registered under the Election Act, 604-893-2200
We value our readers opinions, please send any comment, suggestion or concerns to info@bcpwa.org
Copyright © 2001-2008 BC Persons With AIDS Society. All rights reserved.
Designated trademarks and brands are the property of their respective owners.